Supraj Rajagopalan - Medpace Holdings Independent Director
| MEDP Stock | USD 395.93 6.16 1.58% |
Director
Dr. Supraj R. Rajagopalan is an Independent Director of the Company. Dr. Rajagopalan joined Cinven in 2004 and was a partner since 2011. He currently leads Cinvens Healthcare sector team, sits on the firms Executive Committee and is a member of the UK and Ireland regional team. From 2003 to 2004, he worked for The Boston Consulting Group, where he focused on projects in the financial services and healthcare sectors. Prior to this, he was a doctor in the UK National Health Service from 2001 to 2002. Dr. Rajagopalan has extensive experience serving as a director for a diverse group of European private and public companies. Dr. Rajagopalan graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences since 2014.
| Age | 38 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 5375 Medpace Way, Cincinnati, OH, United States, 45227 |
| Phone | 513 579 9911 |
| Web | https://www.medpace.com |
Medpace Holdings Management Efficiency
The company has return on total asset (ROA) of 0.1389 % which means that it generated a profit of $0.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6135 %, meaning that it created $0.6135 on every $100 dollars invested by stockholders. Medpace Holdings' management efficiency ratios could be used to measure how well Medpace Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Medpace Holdings' Return On Capital Employed is relatively stable compared to the past year. As of 04/28/2024, Return On Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop 0.16. At this time, Medpace Holdings' Total Current Liabilities is relatively stable compared to the past year. As of 04/28/2024, Non Current Liabilities Total is likely to grow to about 182.2 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.3 B.Similar Executives
| Found 11 records | DIRECTOR Age | ||
| YoungJin Kim | Rezolute | N/A | |
| David Welch | Rezolute | 56 | |
| Raquel MS | HCW Biologics | N/A | |
| Yoshio Ishizaka | MediciNova | 78 | |
| Young Sung | Rezolute | N/A | |
| Hoyoung Huh | Rezolute | 47 | |
| Yutaka Kobayashi | MediciNova | 54 | |
| Hideki Nagao | MediciNova | 64 | |
| Gilbert Labrucherie | Rezolute | 44 | |
| Tae Kim | Rezolute | 34 | |
| Samir Patel | Rezolute | 46 | |
Management Performance
| Return On Equity | 0.61 | ||||
| Return On Asset | 0.14 |
Medpace Holdings Leadership Team
Elected by the shareholders, the Medpace Holdings' board of directors comprises two types of representatives: Medpace Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medpace. The board's role is to monitor Medpace Holdings' management team and ensure that shareholders' interests are well served. Medpace Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medpace Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Burwig, Senior Vice President - Operations | ||
| Cornelius McCarthy, Director | ||
| Anastasya Molodykh, Director | ||
| Kevin Brady, CFO Treasurer | ||
| Jesse Geiger, CFO, COO - Laboratory Operations | ||
| Stephen JD, General Officer | ||
| Stephen Ewald, General Counsel, Corporate Secretary | ||
| Bruce Brown, Independent Director | ||
| Matthew Norton, Independent Director | ||
| John MBA, Senior Unit | ||
| MA BSN, Executive Operations | ||
| Ashley Keating, Director | ||
| John Richardson, Director | ||
| Fred Davenport, Director | ||
| August Troendle, Chairman of the Board and Presidentident, CEO | ||
| Alexander Leslie, Independent Director | ||
| Brandon Ebken, Chief Officer | ||
| August MD, Chairman CEO | ||
| Todd Meyers, Vice Marketing | ||
| Reinilde MD, Chief Department | ||
| Weimin MS, VP Biometrics | ||
| Supraj Rajagopalan, Independent Director | ||
| Penelope Bucknell, Vice President - Human Resources | ||
| Daniel OLeary, VP Department | ||
| Brian Carley, Independent Director | ||
| Robert Kraft, Independent Director | ||
| CPA BBA, President | ||
| Lauren Morris, Associate Relations |
Medpace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medpace Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.61 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 11.99 B | ||||
| Shares Outstanding | 30.98 M | ||||
| Shares Owned By Insiders | 18.16 % | ||||
| Shares Owned By Institutions | 81.91 % | ||||
| Number Of Shares Shorted | 984.45 K | ||||
| Price To Earning | 49.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medpace Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Medpace Stock, please use our How to Invest in Medpace Holdings guide.Note that the Medpace Holdings information on this page should be used as a complementary analysis to other Medpace Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Medpace Stock analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Medpace Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medpace Holdings. If investors know Medpace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medpace Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.41 | Earnings Share 9.82 | Revenue Per Share 63.975 | Quarterly Revenue Growth 0.177 | Return On Assets 0.1389 |
The market value of Medpace Holdings is measured differently than its book value, which is the value of Medpace that is recorded on the company's balance sheet. Investors also form their own opinion of Medpace Holdings' value that differs from its market value or its book value, called intrinsic value, which is Medpace Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medpace Holdings' market value can be influenced by many factors that don't directly affect Medpace Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medpace Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medpace Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medpace Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.